These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

851 related items for PubMed ID: 22413944

  • 21. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P, Sigurgeirsson B, Thaci D, Ortonne JP, Paul C, Schopf RE, Morita A, Roseau K, Harfst E, Guettner A, Machacek M, Papavassilis C.
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
    Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R, Gupta P, Krishnaswami S, Tan H, Harness JA.
    Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
    [Abstract] [Full Text] [Related]

  • 23. Etanercept treatment for children and adolescents with plaque psoriasis.
    Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A, Etanercept Pediatric Psoriasis Study Group.
    N Engl J Med; 2008 Jan 17; 358(3):241-51. PubMed ID: 18199863
    [Abstract] [Full Text] [Related]

  • 24. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 17; 24(5):725-33. PubMed ID: 24372225
    [Abstract] [Full Text] [Related]

  • 25. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis.
    Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Brunori M, Mistry S, Bergmans P, Barker J, TRANSIT Investigators.
    Br J Dermatol; 2014 Feb 17; 170(2):435-44. PubMed ID: 24116868
    [Abstract] [Full Text] [Related]

  • 26. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
    Leonardi C, Sobell JM, Crowley JJ, Mrowietz U, Bao Y, Mulani PM, Gu Y, Okun MM.
    Br J Dermatol; 2012 Sep 17; 167(3):658-67. PubMed ID: 22564148
    [Abstract] [Full Text] [Related]

  • 27. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months.
    Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ, Precise 3 Study Investigators.
    Clin Gastroenterol Hepatol; 2010 Jul 17; 8(7):600-9. PubMed ID: 20117244
    [Abstract] [Full Text] [Related]

  • 28. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
    Papp K, Crowley J, Ortonne JP, Leu J, Okun M, Gupta SR, Gu Y, Langley RG.
    Br J Dermatol; 2011 Feb 17; 164(2):434-41. PubMed ID: 21083543
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB.
    J Am Acad Dermatol; 2017 Mar 17; 76(3):418-431. PubMed ID: 28057361
    [Abstract] [Full Text] [Related]

  • 30. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.
    Curtis JR, Chen L, Luijtens K, Navarro-Millan I, Goel N, Gervitz L, Weinblatt M.
    Arthritis Rheum; 2011 Aug 17; 63(8):2203-8. PubMed ID: 21484766
    [Abstract] [Full Text] [Related]

  • 31. Certolizumab pegol for the management of Crohn's disease in adults.
    Rivkin A.
    Clin Ther; 2009 Jun 17; 31(6):1158-76. PubMed ID: 19695385
    [Abstract] [Full Text] [Related]

  • 32. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.
    Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, Baumgartner S.
    N Engl J Med; 2012 Mar 29; 366(13):1181-9. PubMed ID: 22455412
    [Abstract] [Full Text] [Related]

  • 33. Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
    Warren RB, Lebwohl M, Sofen H, Piguet V, Augustin M, Brock F, C Arendt, Fierens F, Blauvelt A.
    J Eur Acad Dermatol Venereol; 2021 Dec 29; 35(12):2398-2408. PubMed ID: 34192387
    [Abstract] [Full Text] [Related]

  • 34. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
    Gordon KB, Warren RB, Gottlieb AB, Blauvelt A, Thaçi D, Leonardi C, Poulin Y, Boehnlein M, Brock F, Ecoffet C, Reich K.
    Br J Dermatol; 2021 Apr 29; 184(4):652-662. PubMed ID: 32652544
    [Abstract] [Full Text] [Related]

  • 35. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
    Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S.
    Aliment Pharmacol Ther; 2010 Jun 29; 31(12):1276-85. PubMed ID: 20298497
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
    Igarashi A, Kato T, Kato M, Song M, Nakagawa H, Japanese Ustekinumab Study Group.
    J Dermatol; 2012 Mar 29; 39(3):242-52. PubMed ID: 21955098
    [Abstract] [Full Text] [Related]

  • 37. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
    Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB.
    Br J Dermatol; 2005 May 29; 152(5):954-60. PubMed ID: 15888152
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB.
    Am J Clin Dermatol; 2010 May 29; 11(4):275-83. PubMed ID: 20513160
    [Abstract] [Full Text] [Related]

  • 39. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K, Papp KA, Blauvelt A, Tyring SK, Sinclair R, Thaçi D, Nograles K, Mehta A, Cichanowitz N, Li Q, Liu K, La Rosa C, Green S, Kimball AB.
    Lancet; 2017 Jul 15; 390(10091):276-288. PubMed ID: 28596043
    [Abstract] [Full Text] [Related]

  • 40. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis.
    Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, Xu H, Xiao R, Ding Y, Huang K, Zhang C, Zhang L, Chen B, Duan X, Pan W, Han G, Chen R, Liu L, Zhang S, Tao J, Pang X, Yu J, Wang H, Zhao Y, Li C, Kang X, Qin L, Zhu X, Su J, Li S, Yang C, Feng W, Lei T, Jiang S, Fang R, Lin M, Lu Q, Xu C, Wang W, Zhang J.
    Br J Dermatol; 2024 Aug 14; 191(3):336-343. PubMed ID: 38366639
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.